Pfizer Ordered to Pay $142 Million for Off-Label Neurontin Marketing

Pfizer has been ordered by a federal court to pay more than $142 million for illegally promoting its anti-seizure medication Neurontin for off-label uses. The U.S. District Court for the District of Massachusetts granted a request from the Kaiser Foundation Health Plan and other plaintiffs to triple the amount of damages Pfizer had originally been ordered by a jury to pay. The court declined, however, to grant additional prejudgment interest to Kaiser, saying, “an award of treble damages will make the plaintiffs whole.” Pfizer agreed with that decision, but still intends to appeal the case, Chris Loder, a spokesman for the company, said.
Drug Industry Daily